Moneycontrol
Get App
SENSEX NIFTY
you are here:

Bliss GVS Pharma Ltd.

BSE: 506197 | NSE: BLISSGVS |

Represents Equity.Intra - day transactions are permissible and normal trading is done in this category
Series: EQ | ISIN: INE416D01022 | SECTOR: Pharmaceuticals

BSE Live

May 26, 13:21
94.50 1.25 (1.34%)
Volume
AVERAGE VOLUME
5-Day
51,896
10-Day
50,060
30-Day
45,700
15,107
  • Prev. Close

    93.25

  • Open Price

    95.00

  • Bid Price (Qty.)

    94.25 (15)

  • Offer Price (Qty.)

    94.60 (20)

NSE Live

May 26, 13:21
94.50 1.30 (1.39%)
Volume
AVERAGE VOLUME
5-Day
136,163
10-Day
116,011
30-Day
114,886
17,413
  • Prev. Close

    93.20

  • Open Price

    93.35

  • Bid Price (Qty.)

    94.30 (2)

  • Offer Price (Qty.)

    94.50 (20)

ANNOUNCEMENTS ON Bliss GVS

  • May 15, 2020 16:39 Source: BSE

    Bliss GVS Pharma - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Please find enclosed herewith a certificate received from Universal Capital Securities Private Limited, Registrar and Share Transfer Agent of the Company under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2020. Kindly take the same on record.

  • May 12, 2020 17:52 Source: BSE

    Bliss GVS Pharma - Statement Of Investor Complaints For The Quarter Ended March 2020

    No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
    1230
    Name of the Signatory :- Aditi Bhatt
    Designation :- Company Secretary and Compliance Officer

  • May 11, 2020 21:25 Source: BSE

    Bliss GVS Pharma - Compliance Certificate - Regulation 7(3) Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended March 31, 2020

    Please find enclosed herewith certificate under Regulation 7(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended March 31, 2020 Kindly take the same on record.

  • May 07, 2020 18:24 Source: BSE

    Bliss GVS Pharma - Shareholding for the Period Ended March 31, 2020

    Bliss GVS Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2020. For more details, kindly Click here

  • Mar 31, 2020 16:54 Source: BSE

    Bliss GVS Pharma - Closure of Trading Window

    This is to inform you that pursuant to Securities Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force) and in accordance with the Code of Internal Procedures and Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons, the Trading window for dealing in securities/shares of Bliss GVS Pharma Limited (''the Company'') will remain closed for all the Designated Persons and their immediate relatives of the Company with effect from Wednesday, April 01, 2020 until 48 hours after the announcement of the audited financial results of the Company for the quarter and year ended March 31, 2020. The Board meeting for declaration of Audited Financial Results for the quarter and year ended March 31, 2020 shall be intimated later.

  • Mar 16, 2020 8:46 Source: NSE

    Bliss GVS Pharma Limited

    Bliss GVS Pharma Limited has informed the Exchange regarding 'Intimation under Regulation 30 of the SEBI (Listing Obligations and DisclosureRequirements) Regulations, 2015 for setting up "New state of the art Oral Solid DosageFacility".'.

  • Mar 16, 2020 8:10 Source: BSE

    Bliss GVS Pharma - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure
    Requirements) Regulations, 2015 For Setting Up "New State Of The Art Oral Solid Dosage
    Facility".

    Pursuant to Regulation 30(6) read with Para B of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company has completed the commissioning &. qualification of Phase-I for its new state of the art multi-product facility situated at Palghar East in Maharashtra. This is the largest manufacturing unit of the Company in terms of planned production capacity when completed. Itis equipped with state of the art process equipment & utilities with a large part of the manufacturing process automated for enhanced levels of productivity, efficiency & compliance while reducing manual intervention.

  • Mar 07, 2020 16:54 Source: BSE

    Bliss GVS Pharma - Grant Of Options Under Bliss GVS Pharma Limited - Employee Stock Options Plan 2019

    Pursuant to Regulation 30 of Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015 (''''Listing Regulations'''') read with Para B of Part A of Schedule III of Listing Regulations and SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015, we would like to inform you that the Members of Nomination and Remuneration Committee of the Board of Directors of the Company in its Meeting held today i.e. March 07, 2020 have approved grant of 27,61,000 Options out of 60,00,000 Options under Bliss GVS Pharma Limited- Employee Stock Options Plan 2019 to the eligible employees as per the details mentioned in Annexure A. You are requested to take the aforementioned information on your records.

  • Mar 04, 2020 9:00 Source: NSE

    Bliss GVS Pharma Limited

    Bliss GVS Pharma Limited has informed the Exchange regarding Clarification/Update Regarding A News Item Dated March 02, 2020 Under Regulation 30(11) Of The SEBI (LODR) Regulations, 2015

  • Mar 03, 2020 21:13 Source: BSE

    Bliss GVS Pharma - Clarification/Update Regarding A News Item Dated March 02, 2020 Under Regulation 30(11) Of The SEBI (LODR) Regulations, 2015

    Enclosed herewith Clarification/Update regarding a news item appearing in media titled ''Bliss GVS Pharma promoters under SEBI lens for insider-trading'' dated March 02, 2020 (online) and March 03, 2020 in newspaper.

BOARD MEETING

Meeting Date : Feb 11, 2020
Remark : Quarterly Results